The combination imatinib + γ-irradiation proved to be significantly synergistic over a broad range of cell growth inhibition levels in both BCR–ABL-positive cell lines and produced the strongest reduction in primary chronic myelogenous leukaemia colony-forming progenitor cells. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.